SSRI medications have come under scrutiny as of late, despite medical experts maintaining they're safe and effective.

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

If it didn’t, I would have failed,” N Dhar, 25, said about living with treatment-resistant depression. And she isn’t ...

In SYMPHONY, AXS-12 was well tolerated with no new safety signals, Thorpy said. The main adverse effects were gastrointestinal, including dry mouth, nausea, constipation, and decreased appetite. One ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...